United States Patent 5,957,886: Scope, Claim Construction, Expiration, and Needleless-Injector Patent Landscape

U.S. Patent No. 5,957,886 covers a needleless injector that combines spring-driven liquid delivery with viscous damping between two relatively movable injector members. The independent claim requires both the injector architecture and a damping mechanism. The patent is directed to a device, not a drug product, and therefore is not an Orange Book-listed drug patent. Its enforceable U.S. patent term has ended, eliminating current infringement exposure based solely on this patent.

What does U.S. Patent 5,957,886 protect?

The patent protects a needleless injector having five core elements:

A first member that a user can hold.
A second member movable relative to the first member.
A liquid outlet through which the dose is injected.
A dispensing member driven by stored spring energy.
A viscous damping mechanism that dampens movement between the first and second members.

Claim 1 is the controlling independent claim. Claims 2 through 9 add narrower limitations.

The patent does not broadly claim every needleless injector. It claims a particular combination of:

Relative movement between injector housing components.
Spring-powered dispensing.
A liquid outlet.
Damping of the relative movement.
A damping medium, expressly described as viscous.

The damping limitation is central. A spring-driven injector without damping would not fall within claim 1 unless another claim element and the applicable claim construction supplied an equivalent damping structure.

Patent identification

Item	Information
U.S. patent	5,957,886
Title	Needleless injector
Technology	Spring-powered needleless liquid injection
Patent type	Utility patent
Core subject matter	Damped relative movement between injector members
Independent claims	Claim 1
Dependent claims	Claims 2-9
FDA Orange Book status	Not an Orange Book drug patent
Current U.S. enforceability	Patent term expired

The patent should be analyzed as a medical-device patent rather than as a conventional drug patent. It does not claim an active pharmaceutical ingredient, a formulation, a method of treating a disease, or a biologic product. Its commercial relevance concerns injector architecture, dose delivery, user actuation, and manufacturing design.

How should claim 1 be construed?

Claim 1 requires an injector with a first user-holdable member and a second member that moves relative to it. The claim does not require the user to hold the first member in a particular orientation, nor does it require a specific housing shape.

The claim also does not expressly require:

A cartridge;
A free piston;
A particular dose volume;
A particular injection pressure;
A specific spring geometry;
A particular damping coefficient;
A needleless injector intended for a particular drug;
A particular actuation sequence.

Those limitations appear in dependent claims or in the specification rather than as universal requirements of claim 1.

Claim 1 limitation map

Claim element	Scope and technical effect
First, user-holdable member	Requires a component capable of being held by the user
Second member movable relative to first member	Requires relative displacement between two injector components
Liquid outlet	Requires an outlet for liquid delivery into a subject
Dispensing member	Requires a component that expels liquid
Spring providing an energy store	Requires stored spring energy, not merely manual force
Damping means	Requires a damping structure that reduces or controls movement
Viscous damping medium	Requires a medium with viscous damping characteristics
Damping of first member relative to second member	Links the damping function to the relative movement of the two members

The phrase "under the force of a spring which provides an energy store" covers both mechanical and compressed-gas spring arrangements because claims 8 and 9 expressly identify those alternatives.

The claim is functional in part. It requires the damping means to be "operable to damp movement." A nominal presence of grease, oil, air, or another medium would not necessarily satisfy the claim if the structure did not perform the required damping function.

What additional injector architecture is protected by claims 2 and 3?

Claims 2 and 3 narrow the invention to a cartridge-and-piston injection system with a latched impact member.

Claim 2

Claim 2 adds:

A cartridge containing the liquid;
A free piston in contact with the liquid;
A latch;
An impact member urged by the spring;
Temporary restraint of the impact member by the latch;
Initial impact against the free piston;
Continued movement of the piston to expel the dose.

The claim therefore covers a two-stage mechanical sequence:

The spring-driven impact member strikes the free piston.
The impact member continues to drive the piston through the cartridge.

This structure distinguishes the claim from injectors in which a piston is driven directly by a plunger without an initial impact event.

Claim 3

Claim 3 requires the latch to be released by movement of the first member relative to the second member in the first direction.

This creates a specific actuation relationship. The relative movement of the injector members is not merely damped; it also performs the latch-release function.

A device that releases the latch through a trigger, button, electronic actuator, or movement in another direction may avoid literal infringement of claim 3 while still potentially implicating claim 1 or claim 2.

Claims 1 through 3: practical scope

Claim	Main limitation	Commercial implication
1	Damped spring-powered injector	Broadest claim; focuses on relative movement and damping
2	Cartridge, free piston, latch, and impact member	Narrows the injector to a specific dose-delivery mechanism
3	Latch released by relative movement in the first direction	Adds a particular actuation sequence

What damping structures are protected by claim 4?

Claim 4 narrows claim 1 to a specific damping arrangement:

A groove in one of the first or second members;
A viscous damping medium in the groove;
An element on the other member;
The element travels through the damping medium.

This claim is directed to a mechanically integrated damping track. The groove and opposing element can be formed in the injector housing, actuator sleeve, piston assembly, or another relatively moving component, provided the claimed relationship is present.

Claim 4 is narrower than claim 1 because it requires a groove-and-element arrangement. A rotary damper, sealed hydraulic cylinder, elastomeric damper, or air dashpot may fall outside the literal wording of claim 4 if it lacks the claimed groove and traveling element.

Likely design-around routes for claim 4

A competing injector could seek to avoid claim 4 by using:

A sealed piston-cylinder damper;
A rotary viscous damper;
A magnetic eddy-current damper;
An elastomeric friction element;
A controlled gas chamber;
Electronic control of an actuator;
Damping located outside the two claimed members;
A structure in which the element does not travel through a groove containing the medium.

Whether any alternative avoids claim 1 would depend on whether it still uses a viscous damping medium to damp movement between the first and second members.

What do claims 5 through 9 cover?

Claims 5 through 9 identify specific damping media and spring types.

Claim	Added limitation	Scope
5	Grease	Covers grease as the viscous damping medium
6	Oil	Covers oil as the viscous damping medium
7	Air	Covers air as the stated damping medium
8	Mechanical spring	Covers a mechanical spring energy store
9	Compressed gas spring	Covers a compressed-gas spring energy store

Claims 5 and 6 are conventional dependent claims directed to grease and oil. Claim 7 is broader in material selection but raises a technical interpretation issue because air is not ordinarily described as a liquid-like viscous medium. In the context of a damping mechanism, air can provide viscous or fluid resistance when forced through a restricted path or displaced by a moving element.

Claims 8 and 9 clarify that the independent claim is not limited to one spring technology. A mechanical spring may include a coil, leaf, disc, or other resilient energy-storage member. A compressed-gas spring may include a pressurized gas chamber or pneumatic energy-storage arrangement.

When did U.S. Patent 5,957,886 lose exclusivity?

The patent's U.S. patent term has ended. The patent therefore does not provide a current enforceable exclusionary right against a competing injector.

For a patent of this vintage, the relevant term is generally measured under the 20-year term rules in 35 U.S.C. §154, subject to any applicable patent-term adjustment, terminal disclaimer, or other term event. The patent was issued in 1999, and its statutory term expired no later than the applicable 20-year term measured from the relevant U.S. filing date. No current patent-term extension associated with a drug approval applies to this device patent.[2]

Exclusivity timeline

Event	Commercial significance
Patent filing and prosecution	Created pending rights and potential continuation or foreign-family rights
Grant in 1999	Created an enforceable U.S. patent right
Patent-term period	Restricted commercial use of the claimed injector architecture
Expiration	Eliminated future infringement liability based solely on the patent
Post-expiration period	Technology can generally be used without a license to this expired patent

Expiration of this patent does not eliminate risk from later patents covering improved injectors, specific cartridges, drug-device combinations, manufacturing processes, or commercial products.

Is U.S. Patent 5,957,886 listed in the Orange Book?

No. The patent is not an Orange Book drug patent.

The FDA Orange Book identifies approved drug products and certain patents or exclusivity information submitted for those products. U.S. Patent 5,957,886 claims a needleless injector device. It does not claim an approved active ingredient, drug formulation, method of use, or drug-delivery system submitted as a listed drug patent.[3]

Regulatory consequences

Because the patent is a device patent:

It is not a basis for a Paragraph IV certification.
It does not block an abbreviated new drug application.
It does not create Hatch-Waxman exclusivity.
It does not create biologic reference-product exclusivity.
It does not receive FDA patent-term extension based on drug approval.
Its relevance would arise through device clearance, combination-product review, or commercial contracting rather than Orange Book listing.

A needleless injector sold with a drug may implicate both FDA device regulation and drug-product regulation. The expired patent would not independently prevent approval or clearance of such a product.

Are there Paragraph IV challenges or biosimilar risks?

There is no conventional Paragraph IV risk associated with this patent because it is not an Orange Book-listed drug patent.

Biosimilar risk is also not applicable. Biosimilar litigation concerns biologic reference products and patents submitted in the relevant biologics framework. U.S. Patent 5,957,886 does not claim a biologic molecule or biologic manufacturing process.

A competitor could nevertheless face patent disputes involving:

A drug formulation delivered through a needleless injector;
A cartridge or disposable dose container;
A specific injector-drug combination;
A method of administering a biologic;
A manufacturing process for high-pressure injection components;
A later-generation injector with electronic control or proprietary dose-setting.

Those rights would need to be identified separately from Patent 5,957,886.

What patent landscape surrounds needleless injectors?

The needleless-injector field has historically included patents on propulsion, nozzle geometry, dose control, cartridges, actuation, safety systems, and user interfaces.

Major technology clusters

Technology cluster	Typical patent subject matter
Spring-powered injectors	Mechanical or pneumatic storage of injection energy
Gas-powered injectors	Compressed gas, gas generators, or pressure chambers
Nozzle systems	Orifice size, jet formation, pressure control, and skin penetration
Cartridge systems	Disposable containers, free pistons, seals, and dose separation
Damping systems	Grease, oil, air, hydraulic, friction, and elastomeric damping
Actuation systems	Triggers, latches, sleeves, buttons, and contact sensing
Dose control	Fixed-dose and adjustable-dose mechanisms
Safety systems	Accidental-fire prevention, lockouts, and user-position detection
Combination products	Injector integration with vaccines, insulin, biologics, or other drugs
Manufacturing	Precision molding, sealing, nozzle fabrication, and assembly methods

Relevant commercial and patent competitors have included Bioject, Antares Pharma, PharmaJet, Crossject, and other developers of needle-free or needleless delivery systems. Their patent estates have generally focused on different combinations of propulsion, nozzle design, cartridges, actuation, and drug-device integration. A competitor’s use of a needleless format alone would not establish infringement of Patent 5,957,886.

How does Patent 5,957,886 compare with broader injector patents?

Patent 5,957,886 is strongest where a product uses:

Two relatively movable housing members;
A spring-driven dispensing mechanism;
Damping of the relative housing movement;
A viscous medium;
A groove-and-element damping arrangement;
A latch released by housing movement;
A free piston in a cartridge.

It is weaker against products that use:

A fixed housing with no claimed relative movement;
A purely gas-powered jet with no spring energy store;
Electronic or motorized actuation;
A nonviscous damping mechanism;
A cartridge driven without an impact member;
A nozzle assembly that does not rely on the claimed housing movement.

How strong was the patent estate?

The patent had meaningful historical value because claim 1 combined several mechanical features that could be integrated into a compact injector. The combination could create design friction for products using a moving outer sleeve, spring-loaded impact member, and viscous damping track.

Its limitations were equally significant:

The claims are device-specific.
Claim 1 requires a spring energy store.
Claim 1 requires damping of movement between two members.
Claims 2 and 3 require a free-piston cartridge and latch sequence.
Claim 4 requires a groove and traveling element.
Claims 5 through 7 identify particular damping media.
The patent does not cover all needleless injection methods.
The patent term has ended.

The expired status is now more important than the historical breadth. A company can generally practice the claimed architecture without licensing this patent, subject to later patents and other legal rights.

What litigation or settlement agreements affect the patent?

No current litigation, Paragraph IV proceeding, or FDA exclusivity dispute is associated with this expired device patent on the facts provided.

Patent disputes in the needleless-injector industry have more commonly involved broader commercial portfolios, later continuation patents, nozzle systems, drug-device combinations, and competing delivery platforms. A settlement involving another patent in the same technology field would not automatically restrict use of the expired claims of Patent 5,957,886.

No license is required solely because a product practices claims 1 through 9 of an expired U.S. patent. Separate contractual restrictions may arise from:

A license to a related patent family;
A supply agreement;
A technology-transfer agreement;
Confidential manufacturing know-how;
A trademark or trade-secret arrangement;
A later patent owned by the same or a successor company.

What generic-launch or product-launch risks remain?

There is no generic-drug launch risk tied directly to Patent 5,957,886. The relevant commercial question is whether a competing injector or combination product may infringe later, unexpired rights.

Low-risk scenarios

A mechanical needleless injector that practices only the expired claims.
A product using a different damping technology.
A device with no relative movement between the claimed members.
A motor-driven or electronically controlled injector.
A product with an independent cartridge and actuator architecture.

Higher-risk scenarios

A spring-powered injector with a moving user sleeve.
A free-piston cartridge driven by an impact member.
A latch released by movement of the injector housing.
A viscous-filled groove and opposing traveling element.
A drug-device combination relying on later injector or formulation patents.

Patent clearance should therefore use Patent 5,957,886 as a historical design reference, not as the endpoint of a freedom-to-operate review.

What geographic coverage did the patent provide?

U.S. Patent 5,957,886 provided rights only in the United States. Foreign protection would have depended on separately filed national applications or regional applications in the relevant patent family.

A U.S. expiration did not automatically determine the status of corresponding rights in:

Europe;
The United Kingdom;
Canada;
Australia;
Japan;
China;
Other national jurisdictions.

Foreign family members may have expired on different dates, lapsed for nonpayment, been abandoned, or never granted. A multinational product launch therefore requires separate country-by-country review of family members and national registers.

What manufacturing and intellectual-property barriers remain?

The expired claims do not eliminate manufacturing barriers. Needleless injectors often require:

Tight nozzle tolerances;
Controlled pressure and dose delivery;
Reliable cartridge sealing;
Repeatable spring force;
Consistent damping characteristics;
Biocompatible materials;
Sterilization compatibility;
Human-factors validation;
Device reliability testing;
Combination-product regulatory controls.

Manufacturing know-how can remain protected as a trade secret after patent expiration. Tooling, validated processes, supplier relationships, and testing protocols can also create practical barriers even when the core patent is no longer enforceable.

Key Takeaways

U.S. Patent 5,957,886 claims a spring-powered needleless injector with viscous damping between two relatively movable members.
Claim 1 is the broadest claim and requires the injector, spring energy store, liquid outlet, dispensing member, and damping function.
Claims 2 and 3 narrow the invention to a free-piston cartridge, impact member, latch, and movement-triggered release.
Claim 4 covers a groove filled with damping medium and an opposing element that travels through it.
Claims 5 through 7 identify grease, oil, and air as damping media.
Claims 8 and 9 cover mechanical and compressed-gas springs.
The patent is a device patent, not an Orange Book drug patent.
Paragraph IV, biosimilar, and Hatch-Waxman exclusivity issues do not apply directly.
The U.S. patent term has ended, so the claims do not create current infringement exposure by themselves.
Later patents on injector systems, formulations, cartridges, nozzles, manufacturing, or drug-device combinations may still affect freedom to operate.
Foreign family members require separate country-specific status analysis.

Frequently Asked Questions

Does Patent 5,957,886 cover all needle-free injectors?

No. It covers a particular spring-powered injector architecture with relative movement between two members and viscous damping of that movement.

Can a company use a grease-damped needleless injector without licensing this patent?

Yes, the expired U.S. patent no longer creates a current licensing requirement by itself. Later patents and contractual rights must be evaluated separately.

Does the patent cover a needleless injector using compressed gas?

Claim 9 expressly covers a compressed-gas spring when the injector also satisfies the limitations of claim 1.

Is air a valid damping medium under claim 7?

Claim 7 expressly identifies air. The device must still use the air to perform the claimed damping function.

Does an injector cartridge create Orange Book patent protection?

No. A cartridge or injector patent is not automatically an Orange Book-listed drug patent. Orange Book treatment depends on the patent’s relationship to an approved drug product and the applicable FDA listing rules.

References

U.S. Patent No. 5,957,886. (1999). Needleless injector. United States Patent and Trademark Office. https://patents.google.com/patent/US5957886
United States Code, 35 U.S.C. § 154. Patent term. https://www.law.cornell.edu/uscode/text/35/154
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	9504878	Mar 10, 1995

PCT Information
PCT Filed	March 08, 1996	PCT Application Number:	PCT/GB96/00551
PCT Publication Date:	September 19, 1996	PCT Publication Number:	WO96/28202

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	204771	⤷ Start Trial
Australia	4949896	⤷ Start Trial
Brazil	9607219	⤷ Start Trial
Canada	2214807	⤷ Start Trial
China	1177305	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 5,957,886